title: Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.
authors.forename: S Tariq
authors.initials: ST
authors.lastname: Sadiq
authors.forename: Salim
authors.initials: S
authors.lastname: Fredericks
authors.forename: Saye H
authors.initials: SH
authors.lastname: Khoo
authors.forename: Phillip
authors.initials: P
authors.lastname: Rice
authors.forename: David W
authors.initials: DW
authors.lastname: Holt
mesh_terms: D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood*; D048588:Benzoxazines; D003521:Cyclopropanes; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000097:blood*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D010078:Oxazines / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000097:blood
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz